# TJ Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tj-biopharma

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.tjbio.com
- Total disclosed funding: $154M
- Latest round: Series C (Sep 30, 2025)
- Investors on record: 14

## About

Founded in 2019 and based in Hangzhou, China, TJ Biopharma is a pharmaceutical company that focuses on biomedical research and development. TJ Biopharma operates R&D bases in Shanghai and Beijing and manufacturing facilities in Hangzhou. In 2022, it achieved GMP production. 

TJ Biopharma was formerly known as I-Mab Biopharma (Hangzhou) Co., Ltd. which was initially a part of the business operations in Greater China of the US-based and Nasdaq-listed pharmaceutical company I-Mab Group. In 2024, following definitive agreements with a group of Chinese investors, I-Mab Group agreed to divest its entire China business, team, and pipeline, along with its existing pipeline and assets (which was then under control of I-Mab Biopharma Co., Ltd., a company located in Shanghai) to the Hangzhou company.  Following the transaction the Hangzhou and Shanghai companies changed their names to TJ Biopharma (Hangzhou) Co., Ltd. and TJ Biopharma (Shanghai) Co., Ltd. respectively, with the latter being a wholly-owned subsidiary of the former (collectively known as TJ Biopharma).

In February 2024, TJ Biopharma raised series C1 funding for more than CNY 500 million. In September 2025, TJ Biopharma raised approximately CNY 600.00 million in series C2 funding led by new investor CICC Capital, with participation from new investors Yijing Investment, Oriental Fortune Capital, Zhike Fund, Chunling Investment and NNFE and returning investors Heda Venture, Tsing Song Capital, Yiyuan (Hangzhou) Private Equity Fund Management and Hangzhou Qiantang Chengfa Technology Service, and other investors.

TJ Biopharma is committed to the research and development, production, certification, and product sales of biopharmaceuticals. The product lines cover diabetes, tumors, autoimmune diseases, and other fields. The company generates revenue from developing biotechnology and biopharmaceutical products.

The series C2 funding will be primarily used to advance Phase III clinical trials and regulatory approvals for first-tier products and accelerate the development of second-tier global innovative drug candidates.

## Funding rounds

- Series C, Sep 30, 2025, $84M — China International Capital Corporation, Oriental Fortune Capital, NNFE, Yijing Investment, Tsing Song Capital, Heda Venture, Yiyuan (Hangzhou) Private Equity Fund Management, Hangzhou Qiantang Chengfa Technology Service, Zhike Fund, Chunling Investment
- Series C, Feb 7, 2024, $70M — I-MAB Biopharma, Heda Venture, Kaitou Hanrun Investment, Tailong VC, Hangzhou Qiantang Chengfa Technology Service, Bruggemoon Limited

## Investors

- I-MAB Biopharma — Series C
- Heda Venture (https://capitalatlas.ai/funds/heda-venture) — Series C
- Kaitou Hanrun Investment (https://capitalatlas.ai/funds/kaitou-hanrun-investment) — Series C
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series C
- Hangzhou Qiantang Chengfa Technology Service — Series C
- Bruggemoon Limited — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series C
- NNFE (https://capitalatlas.ai/funds/nnfe) — Series C
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series C
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series C
- Yiyuan (Hangzhou) Private Equity Fund Management — Series C
- Zhike Fund — Series C
- Chunling Investment — Series C